Mental disorders, religion and spirituality 1990 to 2010: a systematic evidence-based review RM Bonelli, HG Koenig Journal of religion and health 52, 657-673, 2013 | 720 | 2013 |
Frontal-subcortical circuitry and behavior RM Bonelli, JL Cummings Dialogues in clinical neuroscience, 2022 | 717 | 2022 |
CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion JM Lee, EM Ramos, JH Lee, T Gillis, JS Mysore, MR Hayden, SC Warby, ... Neurology 78 (10), 690-695, 2012 | 381 | 2012 |
Religious and spiritual factors in depression: review and integration of the research R Bonelli, RE Dew, HG Koenig, DH Rosmarin, S Vasegh Depression research and treatment 2012, 2012 | 292 | 2012 |
Neuropsychiatric symptoms in a European Huntington's disease cohort (REGISTRY) E van Duijn, D Craufurd, AAM Hubers, EJ Giltay, R Bonelli, H Rickards, ... Journal of Neurology, Neurosurgery & Psychiatry 85 (12), 1411-1418, 2014 | 277 | 2014 |
Identification of genetic variants associated with Huntington's disease progression: a genome-wide association study DJH Moss, AF Pardiñas, D Langbehn, K Lo, BR Leavitt, R Roos, A Durr, ... The Lancet Neurology 16 (9), 701-711, 2017 | 255 | 2017 |
Pharmacological management of Huntington's disease: an evidence-based review RM Bonelli, GK Wenning Current pharmaceutical design 12 (21), 2701-2720, 2006 | 203 | 2006 |
Neuroprotection in Huntington's disease: a 2-year study on minocycline RM Bonelli, AK Hödl, P Hofmann, HP Kapfhammer International clinical psychopharmacology 19 (6), 337-342, 2004 | 148 | 2004 |
A systematic review of the treatment studies in Huntington’s disease since 1990 RM Bonelli, P Hofmann Expert opinion on pharmacotherapy 8 (2), 141-153, 2007 | 139 | 2007 |
Psychotherapie und Spiritualität M Utsch, RM Bonelli, S Pfeifer Springer Berlin Heidelberg, 2014 | 131 | 2014 |
Frontal-subcortical dementias RM Bonelli, JL Cummings The neurologist 14 (2), 100-107, 2008 | 131 | 2008 |
Sexuality in multiple sclerosis EZ Schmidt, P Hofmann, G Niederwieser, HP Kapfhammer, RM Bonelli Journal of Neural Transmission 112, 1201-1211, 2005 | 126 | 2005 |
Huntington's disease: present treatments and future therapeutic modalities RM Bonelli, GK Wenning, HP Kapfhammer International clinical psychopharmacology 19 (2), 51-62, 2004 | 122 | 2004 |
Minocycline for Huntington’s disease: an open label study RM Bonelli, C Heuberger, F Reisecker Neurology 60 (5), 883-884, 2003 | 105 | 2003 |
Prevalence of autoimmune thyroiditis and non-immune thyroid disease in multiple sclerosis G Niederwieser, W Buchinger, RM Bonelli, A Berghold, F Reisecker, ... Journal of neurology 250, 672-675, 2003 | 102 | 2003 |
An international adult guideline for making clozapine titration safer by using six ancestry-based personalized dosing titrations, CRP, and clozapine levels J De Leon, G Schoretsanitis, RL Smith, E Molden, A Solismaa, N Seppälä, ... Pharmacopsychiatry 55 (02), 73-86, 2022 | 93 | 2022 |
Olanzapine for Huntington's disease: an open label study RM Bonelli, FA Mahnert, G Niederwieser Clinical neuropharmacology 25 (5), 263-265, 2002 | 93 | 2002 |
Strukturelles Neuroimaging der Basalganglien bei Schizophrenie: ein Review GN Brandt, RM Bonelli Wiener Medizinische Wochenschrift 158, 84-90, 2008 | 84 | 2008 |
Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study R Reilmann, A McGarry, ID Grachev, JM Savola, B Borowsky, E Eyal, ... The Lancet Neurology 18 (2), 165-176, 2019 | 82 | 2019 |
A review of the treatment options for Huntington’s disease RM Bonelli, P Hofmann Expert Opinion on Pharmacotherapy 5 (4), 767-776, 2004 | 77 | 2004 |